2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

bispecific monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

13

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9963
    Blinatumomab

    Anatumomab

    		 CD19 Cancer
    Blinatumomab (Anatumomab) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab can be used for the research of acute lymphoblastic leukemia .
    Blinatumomab
  • HY-P99238
    Rolinsatamab

    		Interleukin Related Inflammation/Immunology Cancer
    Rolinsatamab is a potent dual IL-4 and IL-13 inhibitor as a fully humanized bispecific monoclonal antibody. Rolinsatamab chimeric antigen receptor sequence T cell. Rolinsatamab can be used in research of immune disease .
    Rolinsatamab
  • HY-P99663
    Inezetamab

    		TNF Receptor Cancer
    Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .
    Inezetamab
  • HY-P99380
    Zanidatamab

    ZW 25

    		 EGFR Cancer
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
    Zanidatamab
  • HY-P99563
    Tibulizumab

    LY 3090106

    		 TNF Receptor Interleukin Related Inflammation/Immunology
    Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research .
    Tibulizumab
  • HY-P9940
    Emicizumab

    		Factor VIII Cardiovascular Disease
    Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research .
    Emicizumab
  • HY-P99676
    Izalontamab

    SI-B001

    		 EGFR Cancer
    Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
    Izalontamab
  • HY-P99330
    Vanucizumab

    Anti-Human VEGFA Recombinant antibody; RO5520985

    		 VEGFR Tie Cancer
    Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects .
    Vanucizumab
  • HY-P99453
    Azintuxizumab

    		ADC Antibody Cancer
    Azintuxizumab is a monoclonal, targeting to B-cell maturation antigen (BCMA) and SLAMF7/CRACC/CD319, IgG1 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM) .
    Azintuxizumab
  • HY-P99354
    Bavunalimab

    Anti-Human CTLA4xLAG3

    		 LAG-3 Inflammation/Immunology Cancer
    Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
    Bavunalimab
  • HY-P99166
    Vudalimab

    		PD-1/PD-L1 CTLA-4 Inflammation/Immunology
    Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .
    Vudalimab
  • HY-P99672
    Istiratumab

    MM 141; MM-005

    		 IGF-1R EGFR Cancer
    Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers .
    Istiratumab
  • HY-P99390
    Tepoditamab

    MCLA 117

    		 CD3 Cancer
    Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
    Tepoditamab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: